JSPR
$1.25
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
Intraday
Recent News
Jasper Therapeutics reports updated data from briquilimab studies
Jasper Therapeutics (JSPR) is reporting positive updated clinical data from Jasper’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU, as well as from the open label extension study in CSU and CIndU. Treatment with briquilimab resulted in rapid disease control in the additional participants enrolled in the 240mg / 180mg Q8W cohort in the BEACON study, with 83% of participants achieving a complete response by week 3 after the initial 240mg dose, and 67% reportin
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Positive Signs As Multiple Insiders Buy Jasper Therapeutics Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Jasper Therapeutics to Halt Asthma Study After Drug Batch Issue; Shares Fall Pre-Bell
Jasper Therapeutics (JSPR) said Monday it is shutting down its asthma trial after discovering a faul
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...